Advanced sterilization products (asp) became aware a patient tested (b)(6) for (b)(6) and was diagnosed in (b)(6) 2013 with acquired immune deficiency syndrome.It was reported a colonoscopy procedure was performed in (b)(6) 2011, using an olympus colonoscope (non-asp product) which was reprocessed in cidex solution.On (b)(6) 2004 (revised on (b)(6) 2004), ats labs prepared protocol # (b)(6) for asp, titled ¿virucidal efficacy of disinfectants for use on inanimate environmental surfaces ¿ virus: (b)(6) type 1¿.The conclusion of this study was that cidex demonstrated complete inactivation of (b)(6) type 1 as required by the united states (b)(4) for virucidal label claims.Asp made a decision to file a fda medwatch report out of an abundance of caution; however, asp does not believe the patient diagnosis was related to use of cidex during scope reprocessing.
|